Copyright
©The Author(s) 2022.
World J Clin Oncol. Apr 24, 2022; 13(4): 276-286
Published online Apr 24, 2022. doi: 10.5306/wjco.v13.i4.276
Published online Apr 24, 2022. doi: 10.5306/wjco.v13.i4.276
Table 3 Mesenchymal-epithelial transition factor inhibitors
| Drug | MET-specific | Type | Other targets | IC50 (nmol/L) |
| Crizotinib | No | Ia | ALK, ROS1 | 22.5 |
| Capmatinib | Yes | Ib | -- | 0.6 |
| Tepotinib | Yes | Ib | -- | 3 |
| Salovitinib | Yes | Ib | -- | 2.1 |
| Bozitinib | Yes | I | -- | 0.51 |
| Cabozantinib | No | II | RET, ROS1, VEGFR2, KIT | 7.8 |
| Merestinib | No | II | TIE-1, AXL, ROS1, DDR1/2, FLT3, MERTK, RON | 8.1 |
| Glesatinib | No | II | MET, VEGFR, RON, TIE-2 | 21.1 |
- Citation: Olmedo ME, Cervera R, Cabezon-Gutierrez L, Lage Y, Corral de la Fuente E, Gómez Rueda A, Mielgo-Rubio X, Trujillo JC, Couñago F. New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2. World J Clin Oncol 2022; 13(4): 276-286
- URL: https://www.wjgnet.com/2218-4333/full/v13/i4/276.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i4.276